Abbott CEO Purchases 18,800 Shares at $107.13, Forecasts 7% Sales Growth
Abbott’s CEO Robert B. Ford purchased 18,800 shares at about $107.13 each, increasing his total stake to 216,203 shares, showing confidence. The company projects 7% sales growth and 10% EPS growth for 2025, backed by double-digit gains in its Medical Devices segment despite Nutrition segment weakness and COVID-19 diagnostics declines.
1. Insider Purchase Signals Strong Confidence
On January 23, 2026, Abbott’s Chairman and Chief Executive Officer Robert Ford acquired 18,800 common shares, increasing his total stake to 216,203 shares. This significant insider transaction demonstrates executive conviction in the company’s strategic direction, especially as Abbott navigates near-term pressures in certain product lines. Such purchases by top management often serve as a positive indicator for long-term investors, reflecting belief in the firm’s ability to execute on its growth initiatives.
2. Medical Devices Drive Outperformance Despite Nutrition Headwinds
Abbott’s Medical Devices segment, led by its Continuous Glucose Monitoring (CGM) franchise, delivered double-digit year-over-year growth in the fourth quarter, effectively offsetting softness in the Nutrition business. While the Nutrition division faced higher manufacturing costs and price-sensitive consumer demand, the diagnostics unit also saw residual declines following elevated COVID-19 testing volumes in the prior year. Analysts maintain a Buy rating on the shares, citing the resilience of the devices portfolio and ongoing innovation pipelines across key product categories.
3. Robust 2025 Financial Targets Underpin Upside
Management has reiterated guidance for 2025, aiming for a 7% increase in consolidated sales and a 10% rise in adjusted earnings per share. These targets are supported by planned product launches in the devices and diagnostics segments, as well as an anticipated normalization in the Nutrition business as cost efficiencies take hold. The forecast underscores Abbott’s ability to balance near-term margin pressures with investments in higher-margin growth areas.
4. Accelerating 2026 Growth and Strategic Acquisition
Looking further ahead, Abbott projects organic revenue growth of 6.5% to 7.5% for 2026, up from mid-single digits the prior year, with adjusted EPS expected to increase by roughly 10% at the midpoint of guidance. In addition, the company is on track to close its acquisition of Exact Sciences in the second quarter of 2026, a move that will introduce a new oncology diagnostics vertical. This transaction is anticipated to broaden Abbott’s addressable market and enhance long-term revenue diversification.